The rapid emergence of human immunodeficiency virus (HIV) strains resistant to available drugs implies that effective treatment modalities will require the use of a combination of drugs targeting different sites of the HIV life cycle. Because the virus cannot replicate without integration into a host chromosome, HIV-1 integrase (IN) is an attractive therapeutic target. Thus, an effective IN inhibitor should provide additional benefit in combination chemotherapy. A four-point pharmacophore has been identified based on the structures of quinalizarin and purpurin, which were found to be potent IN inhibitors using both a preintegration complex assay and a purified enzyme assay in vitro. Searching with this four-point phar-macophore in the 'open' part of the National Cancer Institute three-dimensional structure database produced 234 compounds containing the pharmacophore. Sixty of these compounds were tested for their inhibitory activity against IN using the purified enzyme; 19 were found to be active against IN with IC 50 values of less than 100 µM, among which 10 had IC 50 values of less than 10 µM. These inhibitors can further serve as leads, and studies are in progress to design novel inhibitors based on the results presented in this study.
Following viral infection and reverse transcription, integration of viral DNA into host chromosomal DNA to form a provirus is an essential step, which is mediated by the viral integrase (IN) enzyme (Brown, 1998; Katz & Skalka, 1994; Varmus & Brown, 1989) . IN recognizes attachment sites located at the ends of linear viral DNA and forms an assembled complex with its DNA substrate. Subsequently, highly conserved CA dinucleotides are generally cleaved from the 5′ and 3′ long terminal repeats (LTRs) in viral DNA. IN is packaged together with several viral and cellular proteins to form a preintegration complex (PIC) (Bukrinsky et al., 1993; Farnet & Haseltine, 1991; Farnet et al., 1996; Karageorgos et al., 1993) . After removal of the dinucleotides in the cytoplasm, the PIC migrates to the nucleus and covalently attaches the viral DNA to a host chromosome. These large nucleoprotein complexes are stable during isolation and purification steps and have been used to perform integration reactions in vitro (Bukrinsky et al., 1993; Farnet & Haseltine, 1991; Farnet et al., 1996; Karageorgos et al., 1993) .
Although numerous inhibitors of IN have been identified (Neamati et al., 1997a; Pommier et al., 1997) , selectivity and in vivo potency remain difficult to achieve. At present, two types of assays are generally used to identify inhibitors of this enzyme. High-throughput assays have generally relied on the inhibition of purified IN in vitro. First, expression of IN in bacteria and subsequent purification to homogeneity has allowed rapid isolation of the enzyme and screening of a large number of inhibitors. This assay utilizes recombinant IN, an oligonucleotide sequence corresponding to the LTR, and a divalent metal (Mn 2+ or Mg 2+ ). Although Mg 2+ is more abundant than Mn 2+ in cells and is thought to be more important physiologically than Mn 2+ for in vivo reactions, Mn 2+ is a more efficient cofactor in the in vitro assays and is routinely used. The second type of assay, the PIC assay, is not geared to high-throughput screening at present.
Using both of these assays, Farnet et al. (1996) identified the anthraquinones, quinalizarin and purpurin as IN inhibitors. These compounds exhibited similar potency in Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore Introduction integration and disintegration in vitro as well as in the PIC assay. Interestingly, other known inhibitors of IN, such as the hydroxylated aromatics, were not potent in the PIC assays. Thus, these two compounds (quinalizarin and purpurin) may serve as potential leads for searching and designing novel IN inhibitors.
The concept that a receptor recognizes electronically similar regions on a molecule that are substructurally different but geometrically similar was proposed by Kier (1971) . He defined 'pharmacophore' as the three-dimensional (3D) arrangement of atoms or functional groups that are necessary for a compound to bind to the active site of a specific enzyme or receptor. 3D database pharmacophore searching attempts to identify molecules in a database on the basis of their possessing a particular pharmacophore in their structure, expressed necessarily in three dimensions. This approach has recently gained attention for its ability to discover new leads in drug development programmes (Martin, 1992; Martin et al., 1990; Sheridan et al., 1989; DesJarlais et al., 1990; Bures et al., 1990; Lam et al., 1994) . We have built a 3D structure database of a total of around 407 000 structures from the two-dimensional structures of the National Cancer Institute (NCI) Drug Information System (DIS) database (Milne et al., 1986) using the program Chem-X (Chemical Design, 7 West Way, Oxford, UK) and Corina (Sadowski et al., 1994) . In our laboratory, previous use of this 3D structure database led to the discovery of novel protein kinase C (PK-C) agonists , HIV-1 protease inhibitors and IN inhibitors Neamati et al., 1997a,b; Nicklaus et al., 1997) .
In our previous studies, we compared the 3D structures of reported inhibitors and have generated several threepoint pharmacophores Hong et al., 1997; Neamati et al., 1997a) and a novel four-point pharmacophore (Neamati et al., 1997b) . Subsequent searching of the NCI 3D structure database resulted in the identification of potent inhibitors. Although this approach generated various classes of compounds as inhibitors of IN in vitro, the majority of these compounds exhibited collateral cytotoxicity in cellular assays as a result of their activity against cellular targets. In the present study we have built a 3D energy-minimized structure of quinalizarin and purpurin and identified a common four-point pharmacophore. Subsequent search of the NCI 3D structure database with this pharmacophore produced 234 compounds. Sixty compounds were tested for their inhibitory activity against IN using the purified enzyme and among these compounds, 19 were active against IN with IC 50 values of less than 100 µΜ and 10 with IC 50 values of less than 10 µΜ. Herein, we present the identification of the four-point pharmacophore and anti-IN activity of tested compounds.
Materials and Methods

Chemicals
All compounds were obtained from the NCI chemical repository through the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program were dissolved in DMSO and the stock solutions were stored at -20°C.
Preparation of oligonucleotide substrates
The HPLC purified oligonucleotides AE117, 5′-ACTGC-TAGAGATTTTCCACAC-3′ and AE118, 5′-GTGTG-GAAAATCTCTAGCAGT-3′ were purchased from Midland Certified Reagent Company (Midland, Tex, USA). Purified recombinant IN was prepared as previously described (Mazumder et al., 1998 ). The expression system for the wild-type IN was a generous gift of T Jenkins and R Craigie (Laboratory of Molecular Biology, NIDDK, NIH, Bethesda, Md, USA). To analyse the extent of 3′-processing and strand transfer using 5′ end-labelled substrates, AE118 was 5′ end-labelled using T4 polynucleotide kinase (Gibco BRL) and [γ 32 P]ATP (Dupont-NEN). The kinase was heat-inactivated, AE117 was added, the mixture was heated for 2 min at 95°C, allowed to cool slowly to room temperature and run through a G-25 Sephadex quick spin column (Boehringer Mannheim) to separate annealed doublestranded oligonucleotide from unincorporated label.
IN assays
To determine the extent of 3′ processing and strand transfer, IN was preincubated at a final concentration of 200 nM (optimized concentration for in vitro studies) with the IN inhibitor in a reaction buffer (50 mM NaCl, 1 mM HEPES pH 7.5, 50 µM EDTA, 50 µM DDT, 10% glycerol (w/v), 7.5 mM MnCl 2 , 0.1 mg/ml BSA, 10 mM 2mercaptoethanol, 10% DMSO and 25 mM MOPS, pH 7.2) at 30°C for 30 min. Then, 20 nM of the 5′ end 32 Plabelled linear oligonucleotide substrate was added, and incubation was continued for 1 h. Reactions were quenched by the addition of an equal volume (16 µl) of loading dye (98% deionized formamide, 10 mM EDTA, 0.025% xylene cyanol and 0.025% bromophenol blue). An aliquot (5 µl) was electrophoresed on a denaturing 20% polyacrylamide gel (0.09 M Tris-borate pH 8.3, 2 mM EDTA, 20% acrylamide, 8 M urea).
Gels were dried and analysed using a Molecular Dynamics PhosphorImager. The percentage inhibition was calculated using the following equation:
where C, N, and D are the fractions of 21-mer substrate converted to 19-mer (3′-processing product) or strand transfer products for DNA alone, DNA plus IN, and IN plus drug, respectively. All IC 50 values were determined by plotting the drug concentration versus percentage inhibition and determining the concentration at which 50% inhibition was produced. The values for each drug represent a minimum of four different concentrations that were tested.
3D IN inhibitors database
Over the last few years, a number of classes of IN inhibitors have been identified. We have collected in a 3D database a total of 152 compounds (most of the 152 compounds in the validation database have been previously published; Nicklaus et al., 1997) . Out of these 152 compounds, 77 had shown inhibitory activity with an IC 50 value equal to or less than 100 µM in the 3′-processing assay. This database was built using Chem-X ChemDBS-3D database build and search module. After the 2D structures of all compounds had been drawn using the Edit/2D-Draw module of Chem-X, they were submitted to automatic 3D database generation via ChemDBS-3D. We used the program options to ensure that conformational flexibility of the compounds is taken into account. In addition, we employed keying of this database with 3D distance keys during the build phase (using the 'Search/Generate Keys' option), which allows for rapid screening in subsequent searches with the putative pharmacophores.
The NCI 3D database and search software
The NCI 3D database and the Chem-X program used in both 3D database build and search processes have been described previously by Milne (1986) . The current version of the NCI 3D database consists of 206876 open and 201036 discrete (proprietary) structures, for a total of 407912 structures. All searches reported in this article were conducted only within the open part of the database. The compounds in the database were selected by the NCI between 1955 and 1995 for testing in the NCI anti-cancer screen. The main criterion for addition of a compound to this database has been structural novelty with respect to the compounds already in the database. The conformational flexible search algorithm implemented in Chem-X (July 1994 version; Chemical Design, Oxford, UK) running on a Silicon Graphics IRIS Indigo workstation was used. For flexible compounds, multiple conformations are generated and analysed during both building and searching of the database. A pharmacophore in this study refers to the 3D arrangement of those atoms in a compound that is responsible for the biological activity of the compound. 3D database pharmacophore searching facilitates identification of molecules that meet the requirements specified in the pharmacophore query.
Molecular modelling
All molecular modelling studies were performed with the QUANTA 4.0/CHARMm 22 (Molecular Simulations, Burlington, Mass., USA) molecular modelling package running on a Silicon Graphics IRIS Indigo workstation. Energy minimization was typically computed with 5000 iterations or until convergence (defined as an energy gradient of 0.001 Kcal/mol/Å), using an adjusted basis Newton-Raphson algorithm as implemented in CHARMm. The structures of compounds were built using the ChemNote module with QUANTA and were energyminimized using CHARMm. Conformational searches were conducted using the Monte Carlo random search algorithm implemented in QUANTA.
Chem-X employs a rule-based algorithm in both the database build and search stages. Each single bond is rotated with a default step size of 120°, and each conjugated bond is rotated with a default step size of 180°. Chem-X, thus, covers a much wider conformational space than other 3D database build programs in which only a single conformer is stored. But with such a large step size, the program provides only a limited coverage of the entire conformational space for each compound. Chem-X offers another conformation generation algorithm, the 'Flexifit' method, which is particularly appropriate for structures with a large number of degrees of freedom. In this method each structure is modified by rotation of non-rigid bonds to try to fit the pharmacophore query, without taking into account internal energy changes. The process can be repeated from randomly chosen different starting geometries. Before the 3D search was carried out on the NCI database, these two methods were compared. It was found that the Flexifit method was better suited to the search: more hits were obtained, reducing the possibility of missing active compounds.
Results
Identification of a four-point pharmacophore
The technique of developing a pharmacophore shared by a given set of biologically active molecules, which produce activity by the same mechanism, is based upon several factors. These include deriving preferred conformations via a conformational searching scheme, defining the common groups in terms of specific atom types, general atom types (for example, hydrogen bond acceptor, hydrogen bond donor), or functional groups (for example, charge, hydrophobic centre) and finally on determining the interatomic distance pattern among these pharmacophore centres. Pharmacophores appear to need at least three points of connection, but can have more and the complete pharmacophore can be represented geometrically as a triangle or some other geometric figure. To determine the possible pharmacophore shared by the biologically active conformations of quinalizarin (NSC 4896) and purpurin (NSC 10447), their structures ( Figure 1) were built in the QUANTA ChemNote module. Subsequently, the structures were minimized with the adjusted basis Newton-Raphson algorithm in CHARMm until convergence (defined as an energy gradient of 0.001 Kcal/mol/Å). Then, the minimized structures of quinalizarin and purpurin were superimposed onto each other. It was found that these two compounds possess similar patterns of oxygen atoms. As shown in Figure 2 , four of the oxygen atoms (ball model) can be superimposed with a root meant square (RMS) value of 0.03 Å (Figure 2a ) and 0.02 Å (Figure 2b) . To check which of these two is a reliable pharmacophore model, validation by a search in the small 3D structure database (see Methods) of 152 IN inhibitors was performed. A total of 45 (58.4%) active compounds contain the pharmacophore shown in Figure 2a and 33 (42.8%) active compounds possess the pharmacophore shown in Figure 2b . On this basis, the four-point pharmacophore shown in Figure 2a built from the 3D structures of quinalizarin and purpurin was presumed to be the more probable of the analysed IN pharmacophores and was used in subsequent NCI 3D structure database searches. From the four-point pharmacophore shown in Figure 2a , we can generate four independent three-point pharmacophores with distance patterns: 2.8, 2.8 and 4.9 Å; 2.8, 6.0 and 6.2 Å; 2.8, 5.2 and 6.0 Å; and 4.9, 5.2 and 6.2 Å. The third of these, the three-point pharmacophore with distance pattern of 2.8, 5.2 and 6.0 Å, corresponds to the three-point pharmacophore described previously , which has the dimensions 2.87, 4.76 and 5.62 Å. It was envisioned that four-point pharmacophores should be both more precise and more specific. Compounds that contained a four-point pharmacophore should bind more selectively than those with only a three-point pharmacophore, since the pattern of six distances in a four-point pharmacophore is more stringent than that of the three distances in a three-point pharmacophore. In addition, it is expected that fewer compounds possessing this pharmacophore would be identified in the search. The use of a four-point pharmacophore raises the exciting possibility that pharmacophore searches might be stereoisomeric in character because the four-point pharmacophore is itself chiral. There are however, two difficulties: first, the search algorithm currently in use depends upon interatomic distances and in reducing the pharmacophore to a distance set, its chirality is lost; second, the NCI database, which was built in 1955, contains little reliable chiral information. The pharmacophore centre atoms are shown as balls and other atoms as sticks.
(a)
(b)
Stereochemical pharmacophore searching, which would be expected to reduce significantly the number of false positives derived from searches, therefore remains a future goal.
3D database search
The four-point pharmacophore query shown in Figure 3 was used for searching on the NCI 3D structure database. The distance tolerance in the pharmacophore query was set to 0.8 Å, as shown in Figure 3 . Every atom in the pharmacophore query was allowed to be either oxygen or nitrogen.
The 3D 
Selection of compounds that contain the fourpoint pharmacophore
Structures of the 60 four-point pharmacophore-containing compounds assayed in this study are shown in Figure  4 . The pharmacophore query was built on the basis of the hydrogen bond donating or accepting capabilities of the inhibitors because in many cases, the hydrogen bond interaction provides a major contribution to the overall free energy of binding. Because a basic nitrogen may be capable of behaving as either a hydrogen bond donor or acceptor, a basic nitrogen atom was allowed to replace oxygen in the search, and several of the retrieved compounds contain at least one basic nitrogen atom in the The probable pharmacophore centre atoms or groups are marked with rectangles. *Different compounds in this class use different atoms or groups as the pharmacophore centres. For example, compound 5l uses R 3 , R 4 , R 5 and the ether oxygen atoms as the pharmacophore centres.
* Figure 4 continued pharmacophore assembly. The selection of compounds from the 3D database searching result (234 compounds) for the in vitro assay was based on structural diversity and potential to develop these compounds into drug leads. Therefore, several sulphonates , flavones (Fesen et al., 1994) and other previously reported compounds (Neamati et al., 1997a) were excluded from in vitro testing against IN. Several other of the retrieved compounds were not tested because no sample was available.
In vitro inhibition of IN
During viral infection, IN catalyses two consecutive reac-tions. Initially, it processes linear viral DNA by removing two nucleotides from each 3′ end, leaving the recessed 3′-OH termini. This is followed by transesterification of phosphodiester bonds in which a host DNA strand is cut and the 5′ end of the cut is joined to a processed viral 3′terminus. These two steps, know as 3′-processing and 3′ end-joining (strand transfer or integration), can be readily measured in an in vitro assay employing purified recombinant IN and a 21-mer duplex oligonucleotide corresponding to the U5 end of the HIV LTR sequence (Figure 5a) . A representative gel illustrating inhibition of both 3′-processing and strand transfer reactions by compounds 1, 5, 8, 17, 24 and 25 is shown in Figure 5b . The anti-IN activities of the 60 compounds are shown in Table 1 . All compounds were initially assayed at a concentration of 100 µg/ml. Those that exhibited >50% inhibition at this concentration (for both 3′-processing and strand transfer) were tested at several concentrations to obtain the IC 50 values (Table 1 ). Among the 60 tested compounds, 1,  5, 8, 11, 25, 26, 33, 37, 55 and 58 are potent IN inhibitors with IC 50 values of less than 10 µM. These inhibitors may serve as lead compounds. Previous studies have demonstrated that the catechol-containing compounds are potent inhibitors of IN in vitro (for recent reviews see Neamati et al., 1997c; Pommier et al., 1997) . In many instances, this inhibition is associated with non-specific binding to other cellular targets, and collateral toxicity associated with catechols is of major concern in anti-HIV drug development. Several of the inhibitors reported are analogues of compounds reported previously, for example, a series of flavones were reported as inhibitors of IN (Fesen et al., 1994) . The most active, compound 55, with IC 50 value of less than 1 µM, is a flavone. Quinalizarin and purpurin are flavone derivatives and also show activity against IN.
Antiviral activity
None of the tested compounds including quinalizarin and purpurin protected the HIV-1-infected CEM cells. Some of the inhibitors exhibited considerable toxicity, however, not all compounds were cytotoxic. For example, compounds 1 and 17 exhibited cytotoxic concentration (CC 50 ) values of 12.1 and 15.6 µM against CEM cells, similar to the concentration required for the inhibition of IN. Compounds 8, 55 and 58 with the CC 50 values of 15.7, 78.0 and 13.5 µM were considerably less cytotoxic. However, compounds 11, 23, 46, 47, 56 with the CC 50 values of 0.09, 0.8, 4.0, 0.2 and 3.1 µM, respectively were markedly more cytotoxic than the concentration required to inhibit IN.
Discussion
In this paper we present a four-point pharmacophore and searches based on it in the NCI 3D structure database. The four-point pharmacophore was identified based on the structures of quinalizarin and purpurin, which were reported as IN inhibitors using a PIC assay and purified enzyme assay in vitro (Farnet et al., 1996) .
Discovery of novel IN inhibitors as lead compounds by the use of this four-point pharmacophore may prove that this pharmacophore is one of the possible binding modes for IN inhibitors. It is interesting that the three-point pharmacophore identified previously is subsumed in this four-point pharmacophore. It seems possible that the three-point pharmacophore and the fourpoint pharmacophore are different representations of one binding mode. Although there are no reports indicating that these drugs bind to the exact same site on the IN, interestingly they both possess similar IC 50 values in the purified IN and the PIC assays. In addition, these compounds are similar in size and structure and are superimposable. They also share similar patterns of H-bond donor and acceptor sites. However, both pharmacophore queries yielded active and inactive compounds, which argue for the fact that other properties such as hydrophobicity, steric and electronic factors should also be considered for each inhibitor. In addition, the differences in number of compounds obtained using the two search queries are indications of subtle differences in the energy-minimized structures for these compounds. In this study, we also excluded the sulphur atom, which is a weaker H-bond acceptor than oxygen, from the search query.
The objective of the study presented here was to identify IN inhibitors from a large collection of compounds. The random screening of all the compounds is not practical, nor economical. Therefore, utilizing such technology to select a particular set or subset of compounds that share some structural features could potentiate our efforts in designing a more potent inhibitor. This methodology has been instrumental in identifying inhibitors of protein kinase C (PKC) agonists , HIV-1 protease inhibitors , and IN inhibitors Neamati et al., 1997a,b; Nicklaus et al., 1997) .
At present there is no drug available as a clinical candidate for the inhibition of IN. Also, there are no examples of inhibitors that have been shown to be selective for IN in nanomolar ranges. Therefore, our intent here was to identify lead compounds from which potent inhibitors may be derived. However, no attempt was made to address the question of drug selectivity, intracellular drug uptake and distribution of any of these agents. The fact that only 234 compounds from a list of over 200000 compounds contain such a pharmacophore displays a significant biased for the selection of such compounds, which is only based on the inclusion of H-bond donor or acceptor centres in a molecule. Thus, the results presented here provide additional insights into the growing effort to identify novel inhibitors of IN.
In conclusion, we have demonstrated that starting from known inhibitors of IN, a group of compounds that possess a similar pharmacophore query in 3D can be identified. This methodology coupled with rapid screening of a large number of inhibitors in vitro can provide a powerful means for drug discovery. Application of such methods for discovery of drugs against other targets is also feasible when combined with a searchable 3D database. Cumulatively, the present study shows using quinalizarin and purpurin as leads, several novel inhibitors were discovered with equal or better potency than the parent compounds. Therefore, structural modification of each new hit can further extend the utility of such inhibitors in the in vitro setting.
